UK’s NICE reconsiders backing for lymphoma drug Pixuvri

15 October 2013

The UK drugs watchdog the National Institute for Health and Care Excellence (NICE) has launched a second consultation on draft guidance for Pixuvri (pixantrone), a drug to treat an aggressive form of lymphoma made by US biotech firm Cell Therapeutics (Nasdaq: CTIC).

Earlier this year, NICE declined to recommend use of the drug under the National Health Service after an independent committee of experts concluded there was insufficient evidence to show that pixantrone is more effective than current NHS treatments and it does not represent good value for money for the health service (The Pharma Letter April 11).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >